The pre-clinical and clinical studies described above demonstrate a potential role of Tα1 as adjuvant in melanoma therapy, but whether Tα1 could also play an anti-tumoral activity as monotherapy has remained unclear. This evidence concerns the gene TAAR1 and melanoma.